Sonrotoclax
Beqalzi · BCL-2 inhibitor
2026 second-gen BCL-2 inhibitor, more potent than venetoclax; tumor-lysis AKI is the class risk, managed with mandated dose ramp-up.
Venclexta · Veneto
BCL-2 inhibitor · approved 2016 · 12 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A potent apoptosis inducer whose deep, rapid kill can crash the kidneys with tumor lysis — the mandated ramp-up exists for the kidney.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Tumor lysis syndrome is the defining renal risk, concentrated during the weekly dose ramp-up. Early-development unmitigated dosing caused fatal TLS; with the mandated 5-week ramp-up and risk-stratified prophylaxis, grade 3/4 laboratory TLS fell to 3.1% (MURANO), with clinical TLS rarer still, and structured protocols can drive it near zero.Source: Seymour et al., NEJM 2018 (MURANO; 3.1% grade 3/4 lab TLS)
Acute AKI within hours to days of each ramp-up dose-escalation step.
Distilled from: “Acute — typically within hours to days of each dose-escalation step during the ramp-up.”
The renal outcome is the tumor-lysis story. Under the mandated ramp-up and risk-stratified prophylaxis the lysis is contained: in the prospective real-world VeRVe cohort (239 CLL patients treated per label), clinical TLS occurred in 2.1% and none of those events was fatal or resulted in renal failure. An established oligoanuric TLS with crystal-driven AKI is a different trajectory — recovery then turns on how quickly the metabolic derangement is controlled, which is why the profile's management threshold for starting dialysis is deliberately low.PMID 38421404 (opens PubMed in a new tab)
Two different questions. Quick facts lists this agent's Reversibility as "Partially reversible" — this atlas's reading of the injury across its cited literature. The badge above is narrower: it classes only what the single outcome study cited here reported, which is why the two can differ without either being wrong.
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Clinical tumor-lysis syndrome in 2.1% and laboratory TLS in 6.3% of a prospective real-world CLL cohort (n=239) using the mandated venetoclax ramp-up (VeRVe); none of the clinical events was fatal or caused renal failure.
Not the same figure as §01's 3.1%. §01 is grade 3–4 tumor lysis syndrome in the MURANO trial (venetoclax with rituximab); this row is clinical tumor lysis syndrome in a 239-patient real-world CLL cohort.
Laboratory TLS — hyperkalemia / hyperphosphatemia / hyperuricemia — in 6.3% of the VeRVe real-world CLL cohort on venetoclax with ramp-up.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Crystal / Obstructive Nephropathy strikes: Tubular Lumen.
Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Selective BH3-mimetic inhibitor of the anti-apoptotic protein BCL-2; it displaces pro-apoptotic effectors (BIM/BAX/BAK) to restore mitochondrial apoptosis in malignant cells, producing deep, rapid remissions in CLL/SLL and (with azacitidine/low-dose cytarabine) in AML.
Class-level context for the major non-renal toxicities of the BCL-2 inhibitor class.
Hematologic
Cytopenias, thrombosis, TMA
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
9 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (May 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Due to the increased risk of TLS, patients with reduced renal function (CLcr <80 mL/min, calculated by Cockcroft-Gault formula) require more intensive prophylaxis and monitoring to reduce the risk of TLS when initiating treatment with VENCLEXTA [see Dosage and Administration ( 2.1 , 2.2 , 2.3 , 2.4 ) and Warnings and Precautions ( 5.1 )] . No dose adjustment is recommended for patients with mild, moderate or severe renal impairment (CLcr ≥15 mL/min) [see Clinical Pharmacology ( 12.3 )] .
Kidney rows of the label's dosage tables
From the Venclexta label (May 2026) · DailyMed
No row of this label's 8 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 62,878 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
17,658 of 62,878 reports
Reported with hospitalization
24,262 of 62,878 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 4 of the 62,878 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Venetoclax sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Beqalzi · BCL-2 inhibitor
2026 second-gen BCL-2 inhibitor, more potent than venetoclax; tumor-lysis AKI is the class risk, managed with mandated dose ramp-up.
Gazyva · Anti-CD20 antibody
High tumor-lysis risk in CLL.
Rituxan · Anti-CD20 antibody
Tumor lysis with bulky disease; treats some GN.
Ordspono · Bispecific (CD20×CD3)
CD20×CD3 bispecific; tumor-lysis urate crystal nephropathy with CRS.
Decnupaz · CD123 antibody-drug conjugate
2026 CD123 ADC for BPDCN; renal risk indirect — TLS in the CD123+ disease plus the CD123-class capillary-leak concern; its own dose-limiting toxicity was reversible VOD.
Trisenox · Differentiating agent
Differentiation syndrome; QT prolongation.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.